Foghorn Therapeutics Inc. (FHTX)
After hours:
| Previous close | 5.23 |
| Open | 5.25 |
| Bid | 5.30 x 100 |
| Ask | 5.55 x 100 |
| Day's range | 5.20 - 5.55 |
| 52-week range | 2.70 - 9.97 |
| Volume | |
| Avg. volume | 157,219 |
| Market cap | 233.687M |
| Beta (5Y monthly) | 3.13 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.34 |
| Earnings date | 08 May 2024 - 12 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 13.75 |
GlobeNewswireFoghorn Therapeutics Strengthens Financial Leadership with Appointment of Kristian Humer as Chief Financial Officer
CAMBRIDGE, Mass., April 16, 2024 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that Kristian Humer will join the company as Chief Financial Officer (CFO) on April 16, 2024. Mr. Humer joins Foghorn with over 14 years of diversified financial strategy and business development experience in the life science industry and more
- GlobeNewswire
Foghorn Therapeutics Presents New Preclinical Data on Potential First-in-Class BRM Selective Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Oncology Programs
First-in class BRM (SMARCA2) selective inhibitor FHD-909 demonstrated favorable tolerability and dose-dependent single agent activity in BRG1 mutated cancers preclinically; IND filing on track for Q2 2024 Robust preclinical monotherapy anti-tumor activity for both selective CBP and selective EP300 degrader programs Progress with FHD-909, selective CBP, and selective EP300 degrader programs further validates Foghorn’s drug discovery engine Conference call and webcast today at 5 pm ET / 2 pm PT CA
Simply Wall St.Foghorn Therapeutics (NASDAQ:FHTX) Is In A Good Position To Deliver On Growth Plans
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
